ATE262335T1 - Buprenorphin enthaltende analgetische zusammensetzungen - Google Patents

Buprenorphin enthaltende analgetische zusammensetzungen

Info

Publication number
ATE262335T1
ATE262335T1 AT00977658T AT00977658T ATE262335T1 AT E262335 T1 ATE262335 T1 AT E262335T1 AT 00977658 T AT00977658 T AT 00977658T AT 00977658 T AT00977658 T AT 00977658T AT E262335 T1 ATE262335 T1 AT E262335T1
Authority
AT
Austria
Prior art keywords
compositions containing
containing buprenorphine
analgesic compositions
analgesic
buprenorphine
Prior art date
Application number
AT00977658T
Other languages
English (en)
Inventor
Christopher Bourne Chapleo
Keith Mccormack
Nicolas Calvert Varey
Original Assignee
Reckitt Benckiser Healthcare
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9927359.1A external-priority patent/GB9927359D0/en
Application filed by Reckitt Benckiser Healthcare filed Critical Reckitt Benckiser Healthcare
Application granted granted Critical
Publication of ATE262335T1 publication Critical patent/ATE262335T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT00977658T 1999-11-19 2000-11-17 Buprenorphin enthaltende analgetische zusammensetzungen ATE262335T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9927359.1A GB9927359D0 (en) 1999-11-19 1999-11-19 Improvements in or relating to organic compositions
US17620800P 2000-01-14 2000-01-14
PCT/GB2000/004372 WO2001035942A2 (en) 1999-11-19 2000-11-17 Analgesic compositions containing buprenorphine

Publications (1)

Publication Number Publication Date
ATE262335T1 true ATE262335T1 (de) 2004-04-15

Family

ID=26316086

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00977658T ATE262335T1 (de) 1999-11-19 2000-11-17 Buprenorphin enthaltende analgetische zusammensetzungen

Country Status (31)

Country Link
US (4) US6995169B2 (de)
EP (1) EP1242087B1 (de)
JP (1) JP4745576B2 (de)
KR (1) KR100726699B1 (de)
CN (1) CN100431543C (de)
AR (1) AR031682A1 (de)
AT (1) ATE262335T1 (de)
AU (1) AU777259B2 (de)
BR (1) BR0015580A (de)
CA (1) CA2392013C (de)
CO (1) CO5261517A1 (de)
CZ (1) CZ303160B6 (de)
DE (1) DE60009346T2 (de)
DK (1) DK1242087T3 (de)
ES (1) ES2214334T3 (de)
GB (1) GB2356348B (de)
HK (1) HK1055389A1 (de)
HU (1) HU229565B1 (de)
IL (2) IL149580A0 (de)
MX (1) MXPA02004978A (de)
NO (1) NO321965B1 (de)
NZ (1) NZ519023A (de)
PL (1) PL199727B1 (de)
PT (1) PT1242087E (de)
RO (1) RO121174B1 (de)
RU (1) RU2255737C2 (de)
SI (1) SI21025B (de)
SK (1) SK286888B6 (de)
TR (1) TR200400653T4 (de)
TW (1) TW550070B (de)
WO (1) WO2001035942A2 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR031682A1 (es) * 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20150031718A1 (en) * 2001-08-06 2015-01-29 Purdue Pharma L.P. Pharmaceutical Formulation Containing Opioid Agonist, Opioid Antagonist and Gelling Agent
US7666876B2 (en) 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
DK2316456T3 (en) 2003-04-29 2017-09-11 Orexigen Therapeutics Inc Compositions for affecting weight loss comprising an opioid antagonist and bupropion
CA2569958C (en) 2004-06-12 2016-03-22 Jane C. Hirsh Abuse-deterrent drug formulations
EP3132792B1 (de) * 2005-11-22 2019-09-11 Nalpropion Pharmaceuticals, Inc. Zusammensetzung und verfahren zur erhöhung der insulinempfindlichkeit
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
EP1897543A1 (de) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine-Waffel zur Substitutionstherapie
US20080125592A1 (en) * 2006-10-17 2008-05-29 Penick Corporation Process for preparing oxymorphone, naltrexone, and buprenorphine
CA2674915C (en) * 2006-10-17 2015-06-30 Penick Corporation Process for preparing oxymorphone
EP2089010A1 (de) 2006-10-24 2009-08-19 The John Hopkins University Minitabletten mit schneller freisetzung zur analgesie in labortieren
KR20170077291A (ko) * 2006-11-09 2017-07-05 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
US20080199407A1 (en) 2007-02-15 2008-08-21 Slater Kenneth C Drug Detoxification Protocol Using Microdosing
GB2447013A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition containing buprenorphone and nalmefene
GB2447014A (en) 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition comprising a specific ratio of buprenorphine and naltrexone
GB2447016A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Buprenorphine/naloxone compositions
GB2447015A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition comprising a specific ratio of buprenorphine and naltrexone
EP2197429B9 (de) 2007-09-03 2016-10-26 Nanotherapeutics, Inc. Teilchenzusammensetzung zur abgabe von schwerlöslichen arzneimitteln
US20090082383A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched buprenorphine
JP2011521973A (ja) 2008-05-30 2011-07-28 オレキシジェン・セラピューティクス・インコーポレーテッド 内臓脂肪の状態を処置するための方法
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
AU2011203867B2 (en) 2010-01-11 2015-12-03 Nalpropion Pharmaceuticals Llc Methods of providing weight loss therapy in patients with major depression
SG10201510564PA (en) 2010-12-22 2016-01-28 Purdue Pharma Lp Encased tamper resistant controlled release dosage forms
ES2581323T3 (es) 2010-12-23 2016-09-05 Purdue Pharma Lp Formas de dosificación oral sólida resistentes a alteraciones
PT2706986E (pt) 2011-09-19 2015-07-07 Orexo Ab Nova composição farmacêutica resistente ao abuso para o tratamento da dependência de opiáceos
ES2802048T3 (es) 2012-06-06 2021-01-15 Nalpropion Pharmaceuticals Llc Composición para uso en un método para el tratamiento de sobrepeso y obesidad en pacientes con alto riesgo cardiovascular
JP6406713B2 (ja) 2013-01-30 2018-10-17 ファーモレックス セラピューティクス， インコーポレイテッド 低用量薬剤によるうつ病および他の疾患の処置
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
JP2016529328A (ja) 2013-09-10 2016-09-23 インシス・ファーマ・インコーポレーテッド 舌下ブプレノルフィンスプレー
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
CN106456634A (zh) 2014-04-22 2017-02-22 大塚制药株式会社 布雷帕唑和纳美芬的组合及其用于治疗物质有关的病症的用途
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
CA3166250A1 (en) * 2020-02-05 2021-08-12 Gregory G. Plucinski Drug products for intranasal administration and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
GB8430109D0 (en) 1984-11-29 1985-01-09 Gkn Technology Ltd Securing components
GB8430346D0 (en) * 1984-11-30 1985-01-09 Reckitt & Colmann Prod Ltd Analgesic compositions
GB2213058B (en) * 1987-12-03 1991-07-17 Reckitt & Colmann Prod Ltd Compositions comprising buprenorphine and naltrexone for treatment of opiate addicts
US5512578A (en) * 1992-09-21 1996-04-30 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
US5472943A (en) * 1992-09-21 1995-12-05 Albert Einstein College Of Medicine Of Yeshiva University, Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists
US20010006967A1 (en) * 1992-09-21 2001-07-05 Stanley M. Crain Method of simultaneously enhancing analgesic potency and attenuating adverse side effects caused by tramadol and other bimodally-acting opioid agonists
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
AR031682A1 (es) * 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
JP2004501094A (ja) * 2000-05-05 2004-01-15 ペイン・セラピューティクス・インコーポレイテッド オピオイドアゴニストの効力を増強するか、またはオピオイドアゴニストの有害な副作用を減弱するための新規な組成物および方法

Also Published As

Publication number Publication date
US20060058333A1 (en) 2006-03-16
EP1242087A2 (de) 2002-09-25
NO20022330D0 (no) 2002-05-15
CA2392013C (en) 2009-08-11
SI21025A (sl) 2003-04-30
US20030004178A1 (en) 2003-01-02
DE60009346D1 (de) 2004-04-29
GB2356348A (en) 2001-05-23
NO20022330L (no) 2002-07-04
GB2356348B (en) 2002-02-06
BR0015580A (pt) 2002-07-09
JP4745576B2 (ja) 2011-08-10
DK1242087T3 (da) 2004-07-19
RO121174B1 (ro) 2007-01-30
DE60009346T2 (de) 2005-02-10
HUP0203588A2 (hu) 2003-03-28
KR20020058022A (ko) 2002-07-12
WO2001035942A2 (en) 2001-05-25
PL355330A1 (en) 2004-04-19
ES2214334T3 (es) 2004-09-16
IL149580A (en) 2007-05-15
KR100726699B1 (ko) 2007-06-13
EP1242087B1 (de) 2004-03-24
US20060058332A1 (en) 2006-03-16
RU2255737C2 (ru) 2005-07-10
IL149580A0 (en) 2002-11-10
JP2003514013A (ja) 2003-04-15
CN1413110A (zh) 2003-04-23
PL199727B1 (pl) 2008-10-31
HUP0203588A3 (en) 2005-01-28
AU1529701A (en) 2001-05-30
GB0028088D0 (en) 2001-01-03
RU2002116361A (ru) 2004-01-27
CN100431543C (zh) 2008-11-12
CZ303160B6 (cs) 2012-05-09
TR200400653T4 (tr) 2004-04-21
PT1242087E (pt) 2004-06-30
AU777259B2 (en) 2004-10-07
WO2001035942A3 (en) 2002-06-13
SI21025B (sl) 2008-04-30
US6995169B2 (en) 2006-02-07
TW550070B (en) 2003-09-01
CO5261517A1 (es) 2003-03-31
HU229565B1 (hu) 2014-02-28
US20060069113A1 (en) 2006-03-30
MXPA02004978A (es) 2003-01-28
NO321965B1 (no) 2006-07-31
HK1055389A1 (en) 2004-01-09
AR031682A1 (es) 2003-10-01
WO2001035942A9 (en) 2002-11-28
SK8762002A3 (en) 2002-12-03
US7402591B2 (en) 2008-07-22
SK286888B6 (sk) 2009-07-06
NZ519023A (en) 2004-11-26
CA2392013A1 (en) 2001-05-25

Similar Documents

Publication Publication Date Title
ATE262335T1 (de) Buprenorphin enthaltende analgetische zusammensetzungen
NO20015175D0 (no) Farmasöytisk sammensetning
FI991485A (fi) Uusi farmaseuttinen koostumus
DE60020343D1 (de) Cilostazol enthaltende zubereitung
DE60038698D1 (de) Hydrogel-gesteuerte dosierungsform
CY2007031I1 (el) Συνθεση στοματικης δοσολογιας παρατεταμενης απελευθερωσης
DE60000944D1 (de) Bohrlochzementzusammensetzungen
DK1524266T3 (da) Farmaceutisk sammensætning
ID29785A (id) Komposisi-komposisi sampo
ATE257691T1 (de) Schweisshemmende zusammensetzungen
ITMI991402A0 (it) Composti amorfi e relative composizioni farmaceutiche
DE69925167D1 (de) Hochwitterungsbeständige pulverlackzusammensetzung
DE69943245D1 (de) Gaserzeugende zusammensetzung
PT1239832E (pt) Composicoes farmaceuticas
PT1227817E (pt) Composicao farmaceutica aquosa contendo ciclesonida
FI4488U1 (fi) Farmaseuttinen koostumus
EE200100281A (et) Analgeetiline ravimkoostis
ATE297187T1 (de) Resorcinenthaltende zusammensetzung
EP1169034A4 (de) Decursinol oder seine derivate als analgetika
ID27329A (id) Komposisi penghambat
NO20022845D0 (no) Limsammensetning
DE60029780D1 (de) Biozide zusammensetzungen
ATE252549T1 (de) Aminobutyronitril mischung
ATA36099A (de) Stoffgemisch
DE60020836D1 (de) Flammhemmende zusammensetzungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1242087

Country of ref document: EP